Open AccessEfficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer
Author(s) -
Hiroko Machida,
Aida Moeini,
Marcia A. Ciccone,
Sayedamin Mostofizadeh,
Tsuyoshi Takiuchi,
Laurie L. Brunette,
Lynda D. Roman,
Koji Matsuo
Publication year - 2018
Publication title -
american journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.896
H-Index - 78
eISSN - 1537-453X
pISSN - 0277-3732
DOI - 10.1097/coc.0000000000000394
Subject(s) - medicine , regimen , hazard ratio , univariate analysis , chemotherapy , paclitaxel , cervical cancer , chemotherapy regimen , retrospective cohort study , surgery , adverse effect , salvage therapy , oncology , multivariate analysis , cancer , confidence interval
To examine survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m, administered on day 1, 8, and 15 without day 22).